The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Krasnopol'skaia K.V.

Moskovskiĭ oblastnoĭ NII akusherstva i ginekologii;
kafedra akusherstva i ginekologii FUV MONIKI im. M.F. Vladimirskogo

Sokolova E.A.

Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia;
Novosibirsk State University, Novosibirsk, Russia

Beketova A.N.

Moscow Regional Research Institute of Obstetrics and Gynecology, Ministry of Health of the Moscow Region, Moscow, Russia;
International Clinic «Family», Moscow, Russia

LH-containing gonadotropin preparations in IVF programs (literature review)

Authors:

Krasnopol'skaia K.V., Sokolova E.A., Beketova A.N.

More about the authors

Journal: Russian Journal of Human Reproduction. 2019;25(3): 72‑81

DOI: 10.17116/repro20192503172

Views: 5139

Downloaded: 100

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Krasnopol'skaia KV, Sokolova EA, Beketova AN. LH-containing gonadotropin preparations in IVF programs (literature review). Russian Journal of Human Reproduction. 2019;25(3):72‑81. (In Russ.)
https://doi.org/10.17116/repro20192503172

 
МСФ на ЯМ
Close metadata
Recommended articles:
The role of poly­morphism rs148982377 of the ZNF789 gene in the formation of infe­rtility in patients with endo­metriosis. Russian Journal of Human Reproduction. 2024;(1):64-71
Predictors of success of in vitro fertilization with cryotransfer in patients with chro­nic endo­metritis acco­rding to laser conversion testing. Russian Journal of Human Reproduction. 2024;(2):62-73
Assi­sted reproductive technologies and the risk of placenta accreta. Russian Journal of Human Reproduction. 2024;(3):43-49
Calcium-phosphorus meta­bolism and assi­sted reproductive technologies: inte­rsection points. Russian Journal of Human Reproduction. 2024;(4):19-28
The dile­mma of mana­gement of patients with endo­metrioma and infe­rtility. Russian Journal of Human Reproduction. 2024;(4):29-37
Arti­ficial inte­lligent systems in the deve­lopment of assi­sted reproductive technologies. Russian Bulletin of Obstetrician-Gynecologist. 2024;(2):19-29
Role of hysteroscopy in the diagnosis of uterine pathology in infe­rtility in patients with fami­lial Medi­terranean fever. Russian Bulletin of Obstetrician-Gynecologist. 2024;(2):74-80
Expe­rience of combined treatment of patients with infe­rtility operated for exte­rnal geni­tal endo­metriosis. Russian Bulletin of Obstetrician-Gynecologist. 2024;(3):77-81
Predicting the risk of decreased ovarian rese­rve after surgical treatment of patients with deep infi­ltrative endo­metriosis using arti­ficial inte­lligence. Russian Bulletin of Obstetrician-Gynecologist. 2024;(3):92-102
Correlation depe­ndence of tissue inhi­bitor of meta­lloproteinase-1 levels and follicular fluid morphology in patients with combined (uterine myoma and endo­metriosis) infe­rtility in the ART-programs. Russian Bulletin of Obstetrician-Gynecologist. 2024;(4):21-28

The article presents the current data, analyzing the place of LH-containing gonadotropins in IVF programs. The indications for prescribing drugs with LH-activity, the features of their effects and possible schemes with their use in stimulated cycles are discussed.

Keywords:

infertility
IVF
LH-containing gonadotropins

Authors:

Krasnopol'skaia K.V.

Moskovskiĭ oblastnoĭ NII akusherstva i ginekologii;
kafedra akusherstva i ginekologii FUV MONIKI im. M.F. Vladimirskogo

Sokolova E.A.

Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia;
Novosibirsk State University, Novosibirsk, Russia

Beketova A.N.

Moscow Regional Research Institute of Obstetrics and Gynecology, Ministry of Health of the Moscow Region, Moscow, Russia;
International Clinic «Family», Moscow, Russia

List of references:

  1. Khomburg R. Stimulyatsiya yaichnikov: prakticheskoe rukovodstvo. Per. angl. Pod red. Kogana IYu. M.: GEHOTAR-Media, 2017. (In Russ.)
  2. Krasnopolskaya KV, Kalugina AR. The value of luteinizing hormone in controlled superovulation with gonadotropins in in vitro fertilization programs. Akusherstvo i ginekologiya. 2006;1:3-8. (In Russ.)
  3. Beketova AI, Krasnopol’skaia KV, Nazarenko TA, Kabanova DI. Urinary and recombinant gonadotropins in IVF (a review). Problemy reprodukcii. 2014;20(3):45-52. (In Russ.)
  4. Wolfenson C, Groisman J, Couto AS, Hedenfalk M, Cortvindt RG, Smitz JE, Jespersen S. Batch-to-batch consistency of human-derived gonadotropin preparations compared with recombinant preparations. Reproductive BioMedicine Online. 2005;10(1):442-452. https://doi.org/10.1016/s1472-6483(10)60819-x
  5. Ezcurra D, Humaidan PA. A review f luteinizing hormone and human chorionic gonadotropin when used in assisted reproductive technology. Reproductive Biology and Endocrinology. 2014;12(1):95. https://doi.org/10.1186/1477-7827-12-95
  6. Griesinger G, Diedrich K, Edwarda R.G. Gonadotrophins — past, present and future. Reproductive BioMedicine Online. 2005;10(3):91-92. https://doi.org/10.1016/S1472-6483(11)60396-9
  7. Out H, Mannaeris B, Driessen S, Bennink H. Recombinant FSH (rFSH; Puregon) in assisted reproduction: more oocytes, more pregnancies. Results from five comparative studies. Human Reproduction Update. 1996;2(2):162-171. https://doi.org/10.1093/humupd/2.2.162
  8. Baker VL, Fujimoto VY, Kettel LM, Adamson GD, Hoehler F, Jones CE, Soules MR. Clinical efficacy of highly purified urinary FSH versus recombinant FSH in volunteers undergoing controlled ovarian stimulation for in vitro fertilization: a randomized, multicenter, investigator-blind trial. Ferility and Sterility. 2009;91(4):1005-1011. https://doi.org/10.1016/j.fertnstert.2008.01.064
  9. Jee BC, Sush CS, Kim YB, Kim SH, Moon SY. Clinical efficacy of highly purified hMG versus recombinant FSH in IVF/ICSI cycles: a meta-analysis. Gynecoljgic and Obstetric Investigation. 2010;70(2):32-137. https://doi.org/10.1159/000308458
  10. Wex J, Abou-Setta AM. Economic evaluation of highly purified human menopausal gonadotropin versus recombinant human follicle-stimulating hormone in fresh and frozen in vitro fertilization/intracytoplasmic sperm-injection cycles in Sweden. ClinicoEconomics and Outcomes Research. 2013;9(5):381-397. https://doi.org/10.2147/CEOR.S48994
  11. Levi Setti PE, Alviggi C, Colombo GL, Pisanelli C, Ripellino C, Longobardi S, Canonico PL, De Placido G. Human recombinant follicle stimulating hormone (rFSH) compared to urinary human menopausal gonadotropin (HMG) for ovarian stimulation in assisted reproduction: a literature review and cost evaluation. Journal of Endocrinological Investigation. 2015;38(5):497-503. https://doi.org/10.1007/s40618-014-0204-4
  12. Casper RF. Are recombinant gonadotropins safer, purer and more effective than urinary gonadotropins? Reproductive BioMedicine Online. 2005;11(5):539-540. https://doi.org/10.1016/s1472-6483(10)61155-8
  13. Wade L, Eriksson K, Sluss PM, Hall JE. Serum half-life of pituitary gonadotropins is decreased by sulfonation and increased by sialylation in women. The Journal of Clinical Endocrinology and Metabolism. 2009;94(3):958-964. https://doi.org/10.1210/jc.2008-2070
  14. Frydman R, Howles CM, Truong F. A double-blind, randomized study to compare recombinant human follicle stimulating hormone (FSH; Gonal-F) with highly purified urinary FSH (Metrodin) HP) in women undergoing assisted reproductive techniques including intracytoplasmic sperm injection. The French Multicentre Trialists. Human Reproduction. 2000;15(3):520-525. https://doi.org/10.1093/humrep/15.3.520
  15. Liu X, Hao C, Wang J. Efficacy of Highly Purified Urinary FSH versus Recombinant FSH in Chinese Women over 37 Years Undergoing Assisted Reproductive Techniques. International Journal of Fertility and Sterility. 2015;8(4):385-392. https://doi.org/10.22074/2Fijfs.2015.4178
  16. Coomarasamy A, Afnan M, Cheema D, van der Veen F, Bossuyt PMM, van Wely M. Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and metaanalysis. Human Reproduction. 2008;23(2):310-315. https://doi.org/10.1093/humrep/dem305
  17. Al-Inany HG, Abou-Setta AM, Aboulghar MA, Mansour RT, Serour GI. Efficacy and safety of human menopausal gonadotrophins versus recombinant FSH: a metaanalysis. Reproductive BioMedicine Online. 2008;16(1):81-88. https://doi.org/10.1016/S1472-6483(10)60559-7
  18. Balasch J, Fábregues F. LH in the follicular phase: neither too high nor too low. Reproductive Biomedicine Online. 2006;12(4):406-415. https://doi.org/10.1016/s1472-6483(10)61991-8
  19. Cabrera RA, Stadtmauer L, Mayer JF, Gibbons WE, Oehninger S. Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing hormone agonist and stimulated with recombinant follicle-stimulating hormone. Fertility and Sterility. 2005;83(1):42-48. https://doi.org/10.1016/j.fertnstert.2004.06.050
  20. Hillier SG, Whitelaw PF, Smyth CD. Follicular oestrogen synthesis: the 'two-cell, two-gonadotrophin' model revisited. Molecular and Cellular Endocrinology. 1994;100(1-2):51-55. https://doi.org/10.1016/0303-7207(94)90278-X
  21. Merviel P, Antoine JM, Mathieu E, Millot F, Mandelbaum J, Uzan S. Luteinizing hormone concentrations after gonadotropin-releasing hormone antagonist administration do not influence pregnancy rates in in vitro fertilization-embryo transfer. Fertility and Sterility. 2004;82(1):119-125. https://doi.org/10.1016/j.fertnstert.2003.11.040
  22. Doody K, Devroey P, Gordon K, Witjes H, Mannaerts B. LH concentrations do not correlate with pregnancy in rFSH/GnRH antagonist cycles. Reproductive BioMedicine Online. 2010;20(4):565-567. https://doi.org/10.1016/j.rbmo.2009.12.019
  23. Griesinger G, Shapiro DB, Kolibianakis EM, Witjes H, Mannaerts BM. No association between endogenous LH and pregnancy in a GnRH antagonist protocol: part II, recombinant FSH. Reproductive BioMedicine Online. 2011;23(4):457-465. https://doi.org/10.1016/j.rbmo.2011.06.016
  24. Ramachandran A, Jamdade K, Kumar P, Adiga SK, Bhat RG, Ferrao SR. Is there a Need for luteinizing hormone (LH) estimation in patients undergoing ovarian stimulation with gonadotropin-releasing hormone (GnRH) antagonists and recombinant follicle-stimulating hormone (rFSH)? Journal of Clinical Diagnostic Research. 2014;8(1):90-92. https://doi.org/10.7860/JCDR/2014/5728.3778
  25. Westergaard LG, Laursen SD, Andersen CY. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Human Reproduction. 2000;15(5):1003-1008. https://doi.org/10.1093/humrep/15.5.1003
  26. Propst AM, Hill MJ, Bates GW, Palumbo M, Van Horne AK, Retzloff MG. Low-dose human chorionic gonadotropin may improve in vitro fertilization cycle outcomes in patients with low luteinizing hormone levels after gonadotropin-releasing hormone antagonist administration. Fertility and Sterility. 2011;96(4):898-904. https://doi.org/10.1016/j.fertnstert.2011.06.069
  27. Chen CD, Chiang YT, Yang PK, Chen MJ, Chang CH, Yang YS, Chen SU. Frequency of low serum LH is associated with increased early pregnancy loss in IVF/ICSI cycles. Reproductive BioMedicine Online. 2016;33(4):449-457. https://doi.org/10.1016/j.rbmo.2016.07.001
  28. Yang PK, Wu MY, Chao KH, Chang CH, Chen MJ, Chen SU. Lower rate of early pregnancy loss in patients experiencing early-onset low LH in GnRH antagonist cycles supplemented with menotropin. Journal of the Formosan Medical Association. 2019;118(1/1):92-98. https://doi.org/10.1016/j.jfma.2018.01.012
  29. Tesarik J, Hazout A, Mendoza C. Luteinizing hormone affects uterine receptivity independently of ovarian function. Reproductive BioMedicine Online. 2003;7(1):59-64. https://doi.org/10.1016/S1472-6483(10)61729-4
  30. Berndt S, Perrier d’Hauterive S, Blacher S, Péqueux C, Lorquet S, Munaut C, Applanat M, Hervé MA, Lamandé N, Corvol P, van den Brûle F, Frankenne F, Poutanen M, Huhtaniemi I, Geenen V, Noël A, Foidart JM. Angiogenic activity of human chorionic gonadotropin through LH receptor activation on endothelial and epithelial cells of the endometrium. The FASEB Journal. 2006;20(14):2630-2632. https://doi.org/10.1096/fj.06-5885fje
  31. Hugues JN, Masse-Laroche E, Reboul-Marty J, Boiko O, Meynan C, Cedrin-Durnerin I. Impact of endogenous luteinizing hormone serum levels on progesterone elevation on the day of human chorionic gonadotropin administration. Fertility and Sterility. 2011;96(3):600-604. https://doi.org/10.1016/j.fertnstert.2011.06.061
  32. Weghofer A, Munné S, Brannath W, Chen S, Tomkin G, Cekleniak N, Garrisi M, Barad D, Cohen J, Gleicher N. The impact of LH-containing gonadotropins on diploidy rates in preimplantation embryos: long protocol stimulation. Human Reproduction. 2008;23(3):499-503. https://doi.org/10.1093/humrep/dem412
  33. Zamah AM, Hsieh M, Chen J, Vigne JL, Rosen MP, Cedars MI, Conti M. Human oocyte maturation is dependent on LH-stimulated accumulation of the epidermal growth factor-like growth factor, amphiregulin. Human Reproduction. 2010;25(10):2569-2578. https://doi.org/10.1093/humrep/deq212
  34. Ruvolo G, Bosco L, Pane A, Morici G, Cittadini E, Roccheri MC. Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro fertilization procedures. Fertility and Sterility. 2007;87(3):542-546. https://doi.org/10.1016/j.fertnstert.2006.06.059
  35. Ben-Ami I, Komsky A, Bern O, Kasterstein E, Komarovsky D, and Ron-El R. In vitro maturation of human germinal vesicle-stage oocytes: role of epidermal growth factor-like growth factors in the culture medium. Human Reproduction. 2011;26(1):76-81. https://doi.org/10.1093/humrep/deq290
  36. Huang Y, Zhao Y, Yu Y, Li R, Lin S, Zhang C, Liu P, Qiao J. Altered amphiregulin expression induced by diverse luteinizing hormone receptor reactivity in granulosa cells affects IVF outcomes. Reproductive BioMedicine Online. 2015;30(6):593-601. https://doi.org/10.1016/j.rbmo.2015.03.001
  37. Fleming R, Jenkins J. The source and implications of progesterone rise during the follicular phase of assisted reproduction cycles. Reproductive BioMedicine Online. 2010;21(4):446-449. https://doi.org/10.1016/j.rbmo.2010.05.018
  38. Elgindy EA. Progesterone level and progesterone/estradiol ratio on the day of hCG administration: Detrimental cutoff levels and new treatment strategy. Fertility and Sterility. 2011;95(5):1639-1644. https://doi.org/10.1016/j.fertnstert.2010.12.065
  39. Orvieto R, Nahum R, Meltzer S, Liberty G, Anteby EY, Zohav E. GnRH agonist versus GnRH antagonist in ovarian stimulation: The role of elevated peak serum progesterone levels. Gynecological Endocrinology. 2013;29(9):843-845. https://doi.org/10.3109/09513590.2013.808328
  40. Xu B, Li Z, Zhang H, Jin L, Li Y, Ai J, Zhu G. Serum progesterone level effects on the outcome of in vitro fertilization in patients with different ovarian response: An analysis of more than 10,000 cycles. Fertility and Sterility. 2012;97(6):1321-1327.e1. https://doi.org/10.1016/j.fertnstert.2012.03.014
  41. Yding Andersen C, Bungum L, Nyboe Andersen A, Humaidan P. Preovulatory progesterone concentration associates significantly to follicle number and LH concentration but not to pregnancy rate. Reproductive BioMedicine Online. 2011;23(2):187-195. https://doi.org/10.1016/j.rbmo.2011.04.003
  42. Keef KW, Levis EI, Farland LV, Yanushpolsky E. Progesterone elevation in early and mid-follicular phases in fresh IVF cycles associated with poor clinical pregnancy rate. Fertility and Sterility. 2017; 108(3):e348. https://doi.org/10.1016/j.fertnstert.2017.07.1020
  43. Yang S, Pang T, Li R, Yang R, Zhen X, Chen X, Wang H, Ma C, Liu P, Qiao J. The individualized choice of embryo transfer timing for patients with elevated serum progesterone level on the HCG day in IVF/ICSI cycles: a prospective randomized clinical study. Gynecological Endocrinology. 2015;31(5):355-358. https://doi.org/10.3109/09513590.2014.995620
  44. Venetis CA, Kolibianakis EM, Bosdou J.K., Tarlatzis B.C. Progesterone elevation and probability of pregnancy after IVF: a systematic review and metaanalysis of over 60 000 cycles. Human Reproduction Update. 2013;19(5):433-457. https://doi.org/10.1093/humupd/dmt014
  45. Krasnopol’skaia KV, Gorskaia OS, Kabanova DI, Krstich EV. The influence of progesterone level at the day of HCG administration upon the efficiency of IVF. Problemy reprodukcii. 2012;18(3):42-44. (In Russ.)
  46. Bosh E, Labarta E, Crespo J, Simon C, Remohi J, Pellicer A. Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis. Fertilility and Sterility. 2011;95(3):1031-1036. https://doi.org/10.1016/j.fertnstert.2010.10.021
  47. Lehert P, Kolibianakis EM, Venetis CA, Schertz J, Saunders H, Arriagada P, Copt S, Tarlatzis B. Recombinant human follicle-stimulating hormone (r-hFSH) plus recombinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology: systematic review and metaanalysis. Reproductive Biology and Endocrinology. 2014;12:17. https://doi.org/10.1186/1477-7827-12-17
  48. Devroey P, Pellicer A, Nyboe Andersen A, Arce JC, and Menopur in GnRH Antagonist Cycles with Single Embryo Transfer Trial Group. A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer. Fertility and Sterility. 2012;97(3):561-571. https://doi.org/10.1016/j.fertnstert.2011.12.016
  49. König TE, van der Houwen LE, Overbeek A, Hendriks ML, Beutler-Beemsterboer SN, Kuchenbecker WK, Renckens CN, Bernardus RE, Schats R, Homburg R, Hompes PG, Lambalk CB. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study. Human Reproduction. 2013;28(10):2804-2812. https://doi.org/10.1093/humrep/det266
  50. Xiong Y, Bu Z, Dai W, Zhang M, Bao X, Sun Y. Recombinant luteinizing hormone supplementation in women undergoing in vitro fertilization/intracytoplasmic sperm injection with gonadotropin releasing hormone antagonist protocol: a systematic review and meta-analysis. Reproductive Biology and Endocrinology. 2014;12(1):109. https://doi.org/10.1186/1477-7827-12-109
  51. Vuong TN, Phung HT, Ho MT. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial. Human Reproduction. 2015;30(5):1188-1195. https://doi.org/10.1093/humrep/dev038
  52. Nazarenko TA, Mamedova NR, Monakhova IV, Amirova AA. The choosing of gonadotropins for ovary stimulation in IVF programs. Problemy reprodukcii. 2012;18(3):45-49. (In Russ.)
  53. Krasnopol’skaya KV, Nazarenko TA, Beketova AN, Ivakhnenko VN. The influence of Pergoveris and high starting dose of rFSH on IVF efficiency in patients with high risk of poor respond. Problemy reproduktsii. 2013;19(3):36-41. (In Russ.)
  54. Krasnopol’skaia KV, Nazarenko TA, Beketova AN, Ivakhnenko VN, Kabanova DI. Lh-containing recombinant and urinary gonadotropins in the prevention of poor ovarian response in IVF-et. Problemy reproduktsii. 2013;19(4):67-70. (In Russ.)
  55. Mochtar MH, Danhof N, Olugbenga Ayeleke R, van der Veen F, van Wely M. Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles. Cochrane Database of Systematic Reviews. 2017; 5:CD005070. https://doi.org/10.1002/14651858.cd005070.pub3
  56. Wunsch A, Sonntag B, Simoni M. Polymorphism of the FSH receptor and ovarian response to FSH. Annales d’Endocrinologie. 2007; 68(2-3):160-166. https://doi.org/10.1016/j.ando.2007.04.006
  57. Alviggi C, Clarizia R, Pettersson K, Mollo A, Humaidan P, Strina I, Coppola M, Ranieri A, D’Uva M, De Placido G. Suboptimal response to GnRHa long protocol is associated with a common LH polymorphism. Reproductive BioMedicine Online. 2009;18(1):9-14. https://doi.org/10.1016/s1472-6483(11)60011-4
  58. Filicori M, Cognigni GE, Taraborrelli S, Spettoli D, Ciampaglia W, Tabarelli De Fatis C, Pocognoli P, Cantelli B, Boschi S. Lutheinizing hormone activity in menotropins optimizes folliculogenesis and treatment in controlled ovarian stimulation. Journal of Clinical Endocrinology and Metabolism. 2001;86(1):337-343. https://doi.org/10.1210/jcem.86.1.7108
  59. Turkcapar E, Ozdener T, Batuoglu S. Influence of ovarian stimulation with HMG or recombinant FSH on OHSS prevention in PCO patients undergoing IVF. Fertility and Sterility. 2009;92(3):S96. https://doi.org/10.1016/j.fertnstert.2009.07.1042
  60. Asma E, Elmahaishi MS. Does the Use of Highly Purified Human Menopausal Gonadotrophin (HP-HMG) avoid Ovarian Hyperstimulation Syndrome (OHSS) in Polycystic Ovary (PCO) Patients in Assisted Reproduction (IVF/ICSI)? Gynecology & Obstetrics. 2015;5(2):1000273. https://doi.org/10.4172/2161-0932.1000273
  61. Pacchiarotti A, Sbracia M, Frega A, Selman H, Rinaldi L, Pacchiarotti A. Urinary hMG (Meropur) versus recombinant FSH plus recombinant LH (Pergoveris) in IVF: a multicenter, prospective, randomized controlled trial. Fertility and Sterility. 2010;94(6):2467-2469. https://doi.org/10.1016/j.fertnstert.2010.04.035
  62. Mak SM, Wong WY, Chung HS, Chung PW, Kong GW, Li TC, Cheung LP. Effect of mid-follicular phase recombinant LH versus urinary HCG supplementation in poor ovarian responders undergoing IVF— a prospective double-blinded randomized study. Reproductive Biomedicine Online. 2017;34(3):258-266. https://doi.org/10.1016/j.rbmo.2016.11.014

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.